FDA Approves Frontline Cabozantinib for Advanced RCCJanuary 3rd 2018
The FDA has expanded the label for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma regardless of treatment status. Cabozantinib was initially approved in patients who had previously received anti-angiogenic therapy.
Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated MyelomaDecember 11th 2017
A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I study presented at the ASH Annual Meeting.
FDA Approves First Gene Therapy for Pediatric LeukemiaSeptember 1st 2017
The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Survival Benefit in Myeloma With Lenalidomide Maintenance After TransplantAugust 17th 2017
Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo.
Adult ALL Patients Benefited From Pediatric Regimen Treatment IntensificationJune 27th 2017
Adult patients with early thymic precursor (ETP) acute lymphoblastic leukemia (ALL), a subgroup of T-cell ALL, could benefit from the use of response-based risk stratification and therapy intensification similar to that used in pediatric patients with ETP-ALL.
CAR T-Cell Immunotherapy for Aggressive NHL Effective, Feasible in Real-World SettingDecember 14th 2016
The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response compared with historical outcomes in patients with refractory, aggressive non-Hodgkin lymphoma.
Novel CAR T-Cell Therapy Active in Relapsed, Refractory Multiple MyelomaDecember 3rd 2016
Administration of bb2121, a novel anti–B-cell maturation antigen CAR T-cell therapy, produced anti-tumor responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to interim data from a phase I trial.